BioAmber (BIOA) Getting Somewhat Critical Press Coverage, Analysis Shows
Media stories about BioAmber (NYSE:BIOA) have been trending somewhat negative this week, Accern Sentiment reports. Accern identifies negative and positive press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. BioAmber earned a news impact score of -0.03 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 46.44714152447 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the news articles that may have impacted Accern Sentiment’s analysis:
- BioAmber Inc. (NYSE:BIOA) Experiences Heavy Trading Volume – Modern Readers (modernreaders.com)
- BioAmber Inc. (NYSE:BIOA) Experiences Heavier than Average Trading Volume – Highlight Press (highlightpress.com)
- Technical Indicators for BioAmber Inc. (BIOA) in Short Run – StockNewsGazette (stocknewsgazette.com)
- BioAmber Inc. (NYSE:BIOA) Stock Closed -71.2% Below Its 50 Day Moving Average – Modern Readers (modernreaders.com)
- BioAmber, Inc. :BIOA-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017 (finance.yahoo.com)
BioAmber (NYSE:BIOA) traded up 0.448% on Friday, reaching $0.471. 948,188 shares of the company traded hands. BioAmber has a 52-week low of $0.43 and a 52-week high of $6.50. The firm’s market cap is $17.48 million. The stock has a 50-day moving average price of $1.57 and a 200-day moving average price of $2.34.
BioAmber (NYSE:BIOA) last announced its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.17) by $0.03. The company had revenue of $4.12 million for the quarter, compared to the consensus estimate of $4.09 million. BioAmber had a negative net margin of 221.82% and a negative return on equity of 56.55%. Analysts anticipate that BioAmber will post ($0.58) earnings per share for the current fiscal year.
Several research analysts recently issued reports on BIOA shares. Zacks Investment Research raised shares of BioAmber from a “sell” rating to a “hold” rating in a research report on Wednesday, July 26th. Cowen and Company set a $3.00 price target on shares of BioAmber and gave the stock a “hold” rating in a research report on Monday, July 17th. Finally, ValuEngine raised shares of BioAmber from a “strong sell” rating to a “sell” rating in a research report on Friday, June 23rd.
COPYRIGHT VIOLATION WARNING: “BioAmber (BIOA) Getting Somewhat Critical Press Coverage, Analysis Shows” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/08/26/bioamber-bioa-getting-somewhat-critical-press-coverage-analysis-shows.html.
BioAmber Company Profile
BioAmber Inc (BioAmber), formerly DNP Green Technology, Inc, is an industrial biotechnology company, which produces sustainable chemicals. The Company’s technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products.
Receive News & Stock Ratings for BioAmber Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioAmber Inc. and related stocks with our FREE daily email newsletter.